[go: up one dir, main page]

PE20399A1 - Muteina ob - Google Patents

Muteina ob

Info

Publication number
PE20399A1
PE20399A1 PE00108697A PE00108697A PE20399A1 PE 20399 A1 PE20399 A1 PE 20399A1 PE 00108697 A PE00108697 A PE 00108697A PE 00108697 A PE00108697 A PE 00108697A PE 20399 A1 PE20399 A1 PE 20399A1
Authority
PE
Peru
Prior art keywords
muteina
muteins
making
methods
relates
Prior art date
Application number
PE00108697A
Other languages
English (en)
Inventor
Yves Guisez
Rene Devos
Geert Plaetinck
Der Heyden Jose Van
Sandra Verploegen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20399A1 publication Critical patent/PE20399A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/5759Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

CARACTERIZADA PORQUE COMPRENDE UNA SEQ. ID. 1, CON 146 AMINOACIDOS, EN DONDE EN LA POSICION 127 Ser ES Asp Y EN LA POSICION 128 Arg ES Gln. TAMBIEN SE REFIERE AL METODO DE PRODUCCION DE UNA MUTEINA OB, AL VECTOR DE EXPRESION QUE CODIFICA LA MUTEINA OB Y A LA CELULA HOSPEDADORA SELECCIONADA DE UNA CELULA PROCARIOTA, DE INSECTO o DE MAMIFERO; EN DONDE DICHO METODO DE PRODUCCION COMPRENDE: CULTIVAR UNA CELULA HOSPEDADORA TRANSFORMADA CON LA INSERCION DE UN VECTOR DE EXPRESION, EN UN MEDIO DE CULTIVO ADECUADO PARA LA EXPRESION DE LA MUTEINA, Y, PURIFICAR LA MUTEINA OBTENIDA. ADEMAS SE REFIERE A LOS ANTICUERPOS POLI- Y/O MONOCLONALES CONTRA UNA MUTEINA OB. LA MUTEINA OB ACTUA COMO ANTAGONISTA DE LA PROTEINA DE OBESIDAD HUMANA (LEPTINA), CAUSANDO UN AUMENTO EN EL PESO CORPORAL, SIENDO USADA SOLA O EN COMBINACION CON UN ANTICUERPO MONOCLONAL CONTRA UNA PROTEINA DE LA OBESIDAD, PARA LA PREVENCION, TRATAMIENTO Y CONTROL DE LA OBESIDAD Y DE ENFERMEDADES ASOCIADAS TALES COMO ANOREXIA, CAQUEXIA, TRASTORNOS POR DEMACRACION, ENTRE OTROS
PE00108697A 1996-12-06 1997-12-02 Muteina ob PE20399A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96119606 1996-12-06

Publications (1)

Publication Number Publication Date
PE20399A1 true PE20399A1 (es) 1999-03-05

Family

ID=8223476

Family Applications (1)

Application Number Title Priority Date Filing Date
PE00108697A PE20399A1 (es) 1996-12-06 1997-12-02 Muteina ob

Country Status (8)

Country Link
AR (1) AR010333A1 (es)
AU (1) AU5654998A (es)
CO (1) CO4930295A1 (es)
HR (1) HRP970654A2 (es)
MA (1) MA24411A1 (es)
PE (1) PE20399A1 (es)
WO (1) WO1998024896A2 (es)
ZA (1) ZA9710832B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
CA2725143A1 (en) 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
CN102300581B (zh) 2008-11-04 2016-12-21 尼古拉斯·泰萨普塞蒂斯 用于治疗因神经原纤维缠结和β淀粉状蛋白的积聚引起的进行性认知功能障碍的瘦蛋白组合物和方法
EP2621515B1 (en) 2010-09-28 2017-03-29 Aegerion Pharmaceuticals, Inc. A chimeric seal-human leptin polypeptide with increased solubility

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1259923A (en) * 1983-08-17 1989-09-26 Roger Aston Physiologically active compositions
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
YU5396A (sh) * 1995-01-31 1998-08-14 Eli Lilly And Company, Lilly Corporate Center Novi biološki aktivni proteini, njihove farmaceutske formulacije i postupak za njihovo dobijanje
GB9509164D0 (en) * 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
CO4930295A1 (es) 2000-06-27
HRP970654A2 (en) 1998-10-31
MA24411A1 (fr) 1998-07-01
WO1998024896A2 (en) 1998-06-11
ZA9710832B (en) 1998-06-08
AU5654998A (en) 1998-06-29
AR010333A1 (es) 2000-06-07
WO1998024896A3 (en) 1998-10-01

Similar Documents

Publication Publication Date Title
TR200100056T2 (tr) Nörotrofik faktörler
ATE252639T1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
ID18189A (id) Dervat-derivat 6,6-hetero-bisiklik yang disubstitusi
ID18249A (id) Turunan 6,5-hetero-bisiklik tersubstitusi
TR199601002A1 (tr) 2-Okzo- ve 2-thio-1, 2-dihidrokinolinil-oksazolidinonlar.
DK0901488T3 (da) 2,4-diaminopyrimidinderivater
DK0929299T3 (da) Substituerede 1,2,3,4-tetrahydro-2-dibenzofuranaminer og 2-aminocyclohepta-(b)benzofuraner
PE20399A1 (es) Muteina ob
IL139604A0 (en) Novel peptides
SE9602822D0 (sv) New receptor
ID19571A (id) Proses pemurnian 1,4-butanadiol mentah
FI902803A7 (fi) DNA-sekvenssi, joka koodaa a-amylaasi-pullulanaasientsyymiä
DE69930370D1 (de) Testisspezifische, menschliche proteinase, svph1-8
DE59704842D1 (de) Reihenklemme, insbesondere Initiator-Aktor-Klemme
FR2720419B1 (fr) Bloc artificiel.
IT1302971B1 (it) Procedimento di produzione per prosciutti, e mezzi relativi alprocedimento
ES2122912A1 (es) Inhibidores de metalocarboxipeptidasas y moleculas derivadas como agentes antitumorales.
ID16030A (id) Proses pembuatan turunan 1,5-benzotiazepin
ATE348109T1 (de) Das gen prv-1 und dessen verwendung
ITGE960040A0 (it) Pentapeptide.
ES1033200Y (es) Linterna - caramelo.
ES1035219Y (es) Chincheta-clip.
ES1034158Y (es) Arsonvalizador.
ES1033500Y (es) Caja-expositor.
ES1034580Y (es) Pieza deslizante -saltadora.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal